{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:48:06Z","timestamp":1788994086229,"version":"build-2803163510"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We examined the efficacy and tolerability of calcitonin gene\u2013related peptide\u2013targeted monoclonal antibodies (CGRP-targeted mAbs) as add-on therapy for patients with chronic migraine (CM) undergoing treatment with onabotulinumtoxinA (onabot) who require additional preventive therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We reviewed medical records of patients with CM receiving treatment with onabot who were subsequently prescribed a CGRP-targeted mAb medication. The primary outcome was the change in number of monthly headache days (MHDs) reported. Secondary outcomes were change in headache pain severity, discontinuation due to lack of tolerability, and severe adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 153 patients, 111 (72.5%) reported a decrease in either MHDs or headache pain severity, with documentation of MHDs in 66 patients. Among these 66 patients, the average number of MHDs before initiation of onabot treatment was 25.7. After onabot treatment, an average decrease of 10.9 MHDs was reported (P\u2009&amp;lt;\u20090.001). After the addition of a CGRP-targeted mAb medication, patients experienced a further decrease of 5.7 MHDs (P\u2009&amp;lt;\u20090.001). With combined therapy, patients reported a total decrease of 16.6 MHDs (P\u2009&amp;lt;\u20090.001). Adverse effects occurred in 13 patients (8.5%) after addition of the CGRP-targeted mAb and included constipation, injection site reaction, and fatigue. No serious adverse events were reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Adding a CGRP-targeted mAb to onabot in patients with CM was associated with further reductions in MHDs without major tolerability issues across a range of mAbs. This retrospective review supports the conduct of a well-designed double-blind study adding a CGRP-targeted mAb or placebo to onabot.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/pm\/pnab093","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T12:13:32Z","timestamp":1614860012000},"page":"1857-1863","source":"Crossref","is-referenced-by-count":53,"title":["Efficacy and Tolerability of Calcitonin Gene\u2013Related Peptide\u2013Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3436-2846","authenticated-orcid":false,"given":"Fred","family":"Cohen","sequence":"first","affiliation":[{"name":"Department of Medicine, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Armand","sequence":"additional","affiliation":[{"name":"Department of Neurology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B","family":"Lipton","sequence":"additional","affiliation":[{"name":"Department of Neurology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Vollbracht","sequence":"additional","affiliation":[{"name":"Department of Neurology, Columbia University Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"issue":"1","key":"2021080708521670900_pnab093-B1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.amjmed.2017.09.005","article-title":"Headache","volume":"131","author":"Rizzoli","year":"2018","journal-title":"Am J Med"},{"issue":"10","key":"2021080708521670900_pnab093-B2","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/j.1526-4610.2012.02223.x","article-title":"Chronic migraine prevalence, disability, and sociodemographic factors: Results from the American Migraine Prevalence and Prevention Study","volume":"52","author":"Buse","year":"2012","journal-title":"Headache"},{"issue":"8","key":"2021080708521670900_pnab093-B3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","article-title":"Migraine and the trigeminovascular system\u201440 years and counting","volume":"18","author":"Ashina","year":"2019","journal-title":"Lancet Neurol"},{"issue":"2","key":"2021080708521670900_pnab093-B4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1756285616677005","article-title":"Botulinum toxin in the management of chronic migraine: Clinical evidence and experience","volume":"10","author":"Escher","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"2021080708521670900_pnab093-B5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: A randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol"},{"issue":"6","key":"2021080708521670900_pnab093-B6","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: A Phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia"},{"issue":"24","key":"2021080708521670900_pnab093-B7","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"issue":"9","key":"2021080708521670900_pnab093-B8","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"issue":"22","key":"2021080708521670900_pnab093-B9","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2021080708521670900_pnab093-B10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"issue":"13","key":"2021080708521670900_pnab093-B11","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"2021080708521670900_pnab093-B12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","article-title":"European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention","volume":"20","author":"Sacco","year":"2019","journal-title":"J Headache Pain"},{"issue":"7","key":"2021080708521670900_pnab093-B13","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/head.13839","article-title":"The effect of adding calcitonin gene-related peptide monoclonal antibodies to OnabotulinumtoxinA therapy on headache burden: A retrospective observational case series","volume":"60","author":"Ozudogru","year":"2020","journal-title":"Headache"},{"key":"2021080708521670900_pnab093-B14","first-page":"1","article-title":"Erenumab and OnabotulinumtoxinA combination therapy for the prevention of intractable chronic migraine without aura: A retrospective analysis","author":"Armanious","year":"2020","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"1","key":"2021080708521670900_pnab093-B15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s10194-018-0840-8","article-title":"Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study","volume":"19","author":"Blumenfeld","year":"2018","journal-title":"J Headache Pain"},{"issue":"7","key":"2021080708521670900_pnab093-B16","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.cell.2018.11.049","article-title":"CGRP antibodies as prophylaxis in migraine","volume":"175","author":"Edvinsson","year":"2018","journal-title":"Cell"},{"key":"2021080708521670900_pnab093-B17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jocn.2019.07.043","article-title":"OnabotulinumtoxinA wear-off in chronic migraine, observational cohort study","volume":"69","author":"Zidan","year":"2019","journal-title":"J Clin Neurosci"},{"issue":"10","key":"2021080708521670900_pnab093-B18","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/head.13638","article-title":"OnabotulinumtoxinA wear-off phenomenon in the treatment of chronic migraine","volume":"59","author":"Masters-Israilov","year":"2019","journal-title":"Headache"},{"issue":"4):","key":"2021080708521670900_pnab093-B19","first-page":"8","article-title":"Onabotulinumtoxin A (Botox)","volume":"54","author":"Tepper","year":"2014","journal-title":"Headache"},{"issue":"13","key":"2021080708521670900_pnab093-B20","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1177\/0333102420946725","article-title":"Real-world effectiveness and tolerability of erenumab: A retrospective cohort study","volume":"40","author":"Kanaan","year":"2020","journal-title":"Cephalalgia"},{"key":"2021080708521670900_pnab093-B21","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/head.12774","article-title":"Assessing barriers to chronic migraine consultation, diagnosis, and treatment: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study","volume":"56","author":"Dodick","year":"2016","journal-title":"Headache"},{"issue":"8","key":"2021080708521670900_pnab093-B22","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1212\/01.wnl.0000323925.29520.e7","article-title":"Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment","volume":"71","author":"Bigal","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"2021080708521670900_pnab093-B23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/j.pain.0000000000000831","article-title":"The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine","volume":"158","author":"Iyengar","year":"2017","journal-title":"Pain"},{"issue":"44","key":"2021080708521670900_pnab093-B24","doi-asserted-by":"crossref","first-page":"10587","DOI":"10.1523\/JNEUROSCI.2211-17.2017","article-title":"Fremanezumab\u2014a humanized monoclonal anti-CGRP antibody\u2014inhibits thinly myelinated (A\u03b4) but not unmyelinated (C) meningeal nociceptors","volume":"37","author":"Melo-Carrillo","year":"2017","journal-title":"J Neurosci"},{"issue":"11","key":"2021080708521670900_pnab093-B25","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/0333102414527648","article-title":"Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains","volume":"34","author":"Burstein","year":"2014","journal-title":"Cephalalgia"},{"issue":"6","key":"2021080708521670900_pnab093-B26","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/head.13843","article-title":"Dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: Is there a rationale?","volume":"60","author":"Pellesi","year":"2020","journal-title":"Headache"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/painmedicine\/advance-article-pdf\/doi\/10.1093\/pm\/pnab093\/37110356\/pnab093.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/22\/8\/1857\/39606877\/pnab093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/22\/8\/1857\/39606877\/pnab093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T18:17:34Z","timestamp":1628360254000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article\/22\/8\/1857\/6162176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,3,8]]},"published-print":{"date-parts":[[2021,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/pm\/pnab093","relation":{},"ISSN":["1526-2375","1526-4637"],"issn-type":[{"value":"1526-2375","type":"print"},{"value":"1526-4637","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,3,8]]}}}